The association of interleukin‐6 value, interleukin inhibitors, and outcomes of patients with COVID‐19 in New York City-Reference-Cited by-同舟云学术

The association of interleukin‐6 value, interleukin inhibitors, and outcomes of patients with COVID‐19 in New York City

Published:2020-08-25 Issue:1 Volume:93 Page:463-471
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Maeda Tetsuro¹,Obata Reiichiro¹,Rizk DO Dahlia¹,Kuno Toshiki¹^ORCID

Affiliation:

1. Department of Medicine, Icahn School of Medicine at Mount Sinai Mount Sinai Beth Israel New York City New York

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26365

Reference25 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Coronavirus COVID‐19 global cases by the center for systems science and enginerring at Johns Hopkins University.https://coronavirus.jhu.edu/map.html

3. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

4. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

5. Antirheumatic agents in covid-19: is IL-6 the right target?

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection;Microorganisms;2023-11-16

2. COVID-19 and coronary artery disease; A systematic review and meta-analysis;New Microbes and New Infections;2023-06

3. A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions;npj Systems Biology and Applications;2023-04-14

4. The roles of critical pro‐inflammatory cytokines in the drive of cytokine storm during SARS‐CoV‐2 infection;Journal of Medical Virology;2023-04

5. FORCED CHANGE IN RHEUMATOID ARTHRITIS TREATMENT DUE TO COVID-19 PANDEMIC: EFFECTS OF THE SWITCH FROM INTRAVENOUS TOCILIZUMAB TO SUBCUTANEOUS FORM;Rheumatology Quarterly;2023-03-30